Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: IMO Schwartz stock sales may be the key that unravels this conundrum

I'm trying to clarify something that to date, your posts have NOT addressed one way or the other, at least not directly.



As the 10q numbers imply, it seems the value of the 4 license agreements that were entered into that ended the J2.5 litigation were likely to be worth in the neighborhood of $20M to $25M. I remain fairly convinced that the payments received to date will entail the entirety of the financial results to PDS of these license agreements. I know you disagree. However, if my interpretation proves correct or close, would you consider that a "loss" or a "win" to PDS/TPL/PTSC?

Share
New Message
Please login to post a reply